If you have been reading about alpha-MSH analogue and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-18. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms differ |
| Molecular weight | Approximately 1024 g/mol | Calculated for the free base |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and polar solvents | Poorly soluble in non-polar solvents |
| Typical storage | -20 degrees Celsius, dry, protected from light | Refers to the solid form |
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Other tests, such as the total oxidizable precursor assay, use chemical techniques to transform polyfluorinated compounds into perfluorinated compounds, dramatically reducing the diversity of PFAS in the sample.
== Research == In his research, White focused on membrane protein folding and stability, energetics of protein-bilayer interactions, experimentally determined hydrophobicity scales, translocon-assisted folding of membrane proteins, structure of fluid lipid bilayers, and MD simulations of lipid bilayers. His experimental expertise included X-ray diffraction, neutron diffraction, molecular dynamics simulations, calorimetry, physical chemistry, surface chemistry, statistical analysis of protein sequences, electrical impedance methods, planar bilayer methodology, peptide chemistry, and lipid chemistry. White’s lab determined the first fully resolved structure of a fluid lipid bilayer by combining x-ray and neutron diffraction data, and subsequently validated molecular dynamics simulations of fluid bilayers. White wrote a critical review of the principles of membrane folding and stability in 1999 that is among the ten most cited articles in Annual Review of Biophysics. Using a thermodynamic framework, he highlighted three main aspects of membrane protein folding energetics: protein binding and folding in bilayer interfaces, transmembrane helix insertion, and helix-helix interactions. In his paper “Mechanisms of Integral Membrane Protein Insertion and Folding” written in collaboration with Gunnar von Heijne, he evaluated the progress made during the past decade toward understanding translocon-assisted folding of membrane proteins and reviewed the role of basic thermodynamic principles in MP folding and assembly.
=== Detection frequency === The GC-O analysis is carried out by a panel of 6–12 assessors to count the number of participants who perceive an odour at each retention time. This frequency is then used to represent the relative importance of an odorant in the extract. It is also presumed to relate to the intensity of the odorant at the particular concentration, based on the assumption that individual detection thresholds are normally distributed. Two different kinds of data can be reported by this method depending on the data collected. First, if only frequency data is available, it is reported as the nasal impact frequency (NIF) or the peak height of the olfactometric signal. It is zero if no assessor senses the odour and added with one each time an assessor senses an odour. Second, if both frequency of detection and duration of odour are collected, the surface of NIF (SNIF) or the peak area corresponding to the product of frequency of detection (%) and duration of odour (s) can be interpreted. SNIF allows further interpretation of odour compounds other than just peak height. The detection frequency method benefits from its simplicity and lack of requirement for trained assessors, as the signal recorded is binary (presence/absence of odour). On the other hand, a drawback of this method is the limitation to the assumption of the relationship between frequency and perceived odour intensity. Odour-active compounds in food samples are often present at concentrations above their detection thresholds.
Plastination: One method of preserving tissues is plastination, invented by Gunther von Hagens and made famous by the exhibition Body Worlds. The process of plastination involves replacing the water and fat of a specimen with a curable polymer. This form of preservation requires little upkeep in terms of conservation, other than periodic surface cleaning. Wet specimens: A more classic form of soft tissue preservation is in a solution of formaldehyde, creating what is known as a wet specimen. The Mütter Museum in Philadelphia, PA has an extensive collection of wet specimens of human body parts, including both normal specimens and medical abnormalities. Care and hazards of wet specimens can be found on the website of the American Museum of Natural History.
Sources: en.wikipedia.org
By March 1940 the Oxford team had sufficient impure penicillin to commence testing whether it was toxic. Over the next two months, Florey and Jennings conducted a series of experiments on rats, mice, rabbits and cats in which penicillin was administered in various ways. Their results showed that penicillin was destroyed in the stomach, but that all forms of injection were effective, as indicated by assay of the blood. It was found that penicillin was largely and rapidly excreted unchanged in their urine. They found no evidence of toxicity in any of their animals. Had they tested against guinea pigs, research might have halted at this point, for penicillin is toxic to guinea pigs. At 11:00 am on Saturday 25 May 1940, Florey injected eight mice with a virulent strain of Streptococcus, and then injected four of them with the penicillin solution. These four were divided into two groups: two of them received 10 milligrams once, and the other two received 5 milligrams at regular intervals. By 3:30 am on Sunday all four of the untreated mice were dead. All of the treated ones were still alive, although one died two days later. Florey described the result to Jennings as "a miracle." Jennings and Florey repeated the experiment on Monday with ten mice; this time, all six of the treated mice survived, as did one of the four controls. On Tuesday, they repeated it with sixteen mice, administering different doses of penicillin. All six of the control mice died within 24 hours but the treated mice survived for several days, although they were all dead in nineteen days.
=== Adobe ColdFusion 8 === On July 30, 2007, Adobe Systems released ColdFusion 8, dropping "MX" from its name. During beta testing the codename used was "Scorpio" (the eighth sign of the zodiac and the eighth iteration of ColdFusion as a commercial product). More than 14,000 developers worldwide were active in the beta process - many more testers than the 5,000 Adobe Systems originally expected. The ColdFusion development team consisted of developers based in Newton/Boston, Massachusetts and offshore in Bangalore, India. Some of the new features are the CFPDFFORM tag, which enables integration with Adobe Acrobat forms, some image manipulation functions, Microsoft .NET integration, and the CFPRESENTATION tag, which allows the creation of dynamic presentations using Adobe Acrobat Connect, the Web-based collaboration solution formerly known as Macromedia Breeze. In addition, the ColdFusion Administrator for the Enterprise version ships with built-in server monitoring. ColdFusion 8 is available on several operating systems including Linux, Mac OS X and Windows Server 2003.
=== Family === Platt was born on January 12, 1960, in Windsor, Ontario, Canada, to American parents Sheila Maynard, a clinical social worker and Nicholas Platt, a career diplomat who served as U.S. ambassador to Pakistan, Zambia and the Philippines. His older brother, Adam Platt, is a New York magazine restaurant critic. They returned to the United States when Platt was three months old. Platt's paternal great-grandfather was artist and architect Charles A. Platt, and his maternal great-grandparents were equestrian Arthur Scott Burden (of the industrialist Burden family) and socialite Cynthia Roche. Platt is also a great-great-grandson of General Robert Shaw Oliver (through his mother). Platt's paternal great-great-grandfather was diplomat and lawyer Joseph Hodges Choate. Choate was the most successful lawyer in New York City during the Gilded Age and was later appointed U.S. Ambassador to the United Kingdom by President William McKinley. His brother William Gardner Choate, who was also a prominent lawyer and federal judge, created Choate Rosemary Hall.
The resulting dried plasma package came in two tin cans containing 400 mL bottles. One bottle contained enough distilled water to reconstitute the dried plasma contained within the other bottle. In about three minutes, the plasma would be ready to use and could stay fresh for around four hours. Charles R. Drew was appointed medical supervisor, and he was able to transform the test-tube methods into the first successful technique for mass production. Another important breakthrough came in 1937–40 when Karl Landsteiner (1868–1943), Alex Wiener, Philip Levine, and R.E. Stetson discovered the Rhesus blood group system, which was found to be the cause of the majority of transfusion reactions up to that time. Three years later, the introduction by J.F. Loutit and Patrick L. Mollison of acid–citrate–dextrose (ACD) solution, which reduced the volume of anticoagulant, permitted transfusions of greater volumes of blood and allowed longer-term storage. Carl Walter and W.P. Murphy Jr. introduced the plastic bag for blood collection in 1950. Replacing breakable glass bottles with durable plastic bags made from PVC allowed for the evolution of a collection system capable of safe and easy preparation of multiple blood components from a single unit of whole blood. In the field of cancer surgery, the replacement of massive blood-loss became a major problem. The cardiac-arrest rate was high. In 1963 C. Paul Boyan and William S. Howland discovered that the temperature of the blood and the rate of infusion greatly affected survival rates, and introduced blood warming to surgery.
== Future research == The pathophysiology of IIMs is not well understood. Muscle weakness can be caused by a single or combined effect on muscle tissue by inflammation, inflammatory infiltrates, muscle atrophy, metabolic abnormalities that indicate disordered energy metabolism, and possibly neuropathy, among others. Therefore, physical exercise has the potential to cause harm. However, the results of these exercise studies, at minimum, show that exercise can attenuate muscle damage due to disease, inactivity and steroid use. They reflect the benefit of exercise through the strengthening of complement (non-diseased) muscles, and should encourage further studies to confirm whether diseased muscle may experience regeneration. The definition of improvement must be established, and reproducible longitudinal studies must be conducted to determine the efficacy of exercise as therapy for IIM.
Sources: en.wikipedia.org
==== 1–99 ==== Environmental Protection (Controls on Injurious Substances) Regulations 1993 (S.I. 1993/1) Rail Crossing Extinguishment and Diversion Orders Regulations 1993 (S.I. 1993/9) Town and Country Planning (Public Path Orders) Regulations 1993 (S.I. 1993/10) Public Path Orders Regulations 1993 (S.I. 1993/11) Wildlife and Countryside (Definitive Maps and Statements) Regulations 1993 (S.I. 1993/12) Food Protection (Emergency Prohibitions) (Radioactivity in Sheep) Partial Revocation Order 1993 (S.I. 1993/13) Animals (Post-Import Control) Order 1993 (S.I. 1993/14) Genetically Modified Organisms (Contained Use) Regulations 1993 (S.I. 1993/15) Friendly Societies Act 1992 (Commencement No. 3 and Transitional Provisions) Order 1993 (S.I. 1993/16) Food Protection (Emergency Prohibitions) (Oil and Chemical Pollution of Fish) Order 1993 (S.I. 1993/17) Wireless Telegraphy Apparatus (Land Mobile-Satellite Service) (Low Bit Rate Data) (Exemption) Regulations 1993 (S.I. 1993/21) Local Government Finance (Miscellaneous Provisions) (England) Order 1993 (S.I. 1993/22) Lanarkshire (Hamilton) Enterprise Zones Designation Order 1993 (S.I. 1993/23) Lanarkshire (Motherwell) Enterprise Zones Designation Order 1993 (S.I. 1993/24) Lanarkshire (Monklands) Enterprise Zones Designation Order 1993 (S.I. 1993/25) Mayday Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/27) Warrington Hospital National Health Service Trust (Establishment) Order 1993 (S.I. 1993/28) West Midlands Ambulance Service National Health Service Trust (Establishment) Order 1993 (S.I.
=== Other === In traditional Japanese art, alum and animal glue were dissolved in water, forming a liquid known as dousa (ja:礬水), and used as an undercoat for paper sizing. Alum is an ingredient in some recipes for homemade modeling compounds, often called "play clay" or "play dough", intended for use by children. Potassium alum was formerly used as a hardener for photographic emulsions (films and papers), usually as part of the fixer. It has now been replaced in that use by other chemicals.
==== Other countries ==== In Canada, France, the Netherlands, and Germany, mescaline in raw form and dried mescaline-containing cacti are considered illegal drugs. However, anyone may grow and use peyote (Lophophora williamsii) as well as Echinopsis pachanoi and Echinopsis peruviana (San Pedro cactus) without restriction, as they are specifically exempt from legislation. In Canada, mescaline is classified as a schedule III drug under the Controlled Drugs and Substances Act, whereas peyote is exempt. In Russia, mescaline, its derivatives, and mescaline-containing plants are banned as narcotic drugs (Schedule I).
== Potential applications == A wide variety of potential applications have been envisaged. Since magnetic nanoparticles are expensive to produce, there is interest in their recycling or for highly specialized applications. The potential and versatility of magnetic chemistry arises from the fast and easy separation of the magnetic nanoparticles, eliminating tedious and costly separation processes usually applied in chemistry. Furthermore, the magnetic nanoparticles can be guided via a magnetic field to the desired location which could, for example, enable pinpoint precision in fighting cancer.
Sources: en.wikipedia.org
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.
Both are synthetic analogues derived from the same parent hormone. Reference descriptions usually characterise afamelanotide as more selective for the MC1R subtype, whereas melanotan-2 is reported to interact with a wider range of melanocortin receptors.
Early studies explored melanocortin signalling and pigmentation, which later led to informal use of the label tanning peptide. That label is not a regulatory category and does not imply approved status for any purpose.
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.